The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
|Articles|October 2, 2019
- Pharmaceutical Technology\'s In the Lab eNewsletter-11-06-2019
- Volume 14
- Issue 11
Astellas Invests $13 Million into Innovation Facilities for Cell and Gene Therapy
The new incubators are set to be operational starting in 2021.
Advertisement
Astellas Pharma, a pharmaceutical products company based in Tokyo, Japan, announced it will invest $13 million into two innovation incubators from LabCentral, a laboratory facility for biotech start-ups in Cambridge, MA, making Astellas one of the five pharmaceutical/biotechnology companies to sponsor the new incubators.
The incubators will consist of lab space for companies to conduct development studies and a non-GMP pilot plant, according to an Oct. 1, 2019 press release. Supporting the incubators will give the company access to healthcare solutions start-ups and entrepreneurial founders looking to expand cell and gene therapy.
Astellas will also invest around $450,000 over a course of three years to become a Gold Sponsor of LabCentral’s Massachusetts-based incubator.
“Accelerating early-stage scientific innovation in areas such as cell and gene therapy is a strategic focus for Astellas, and is superbly aligned with the mission of LabCentral to serve as a launching-pad for cutting-edge biotech and life sciences start-ups,” said Kenji Yasukawa, PhD, president and CEO, Astellas, in the press release
The incubators are set to be operational starting in 2021.
Source:
Articles in this issue
almost 7 years ago
How Best to Select a Quality Cell-Line Sourcealmost 7 years ago
Reviewing the Basic Principles of Dissolution Testingalmost 7 years ago
New 2D Code Reader by Micronic Guarantees Greater Accuracyalmost 7 years ago
TetraScience Receives Strategic Investment from Watersalmost 7 years ago
Frontage Expands Bioanalytical Capacity and Capabilitiesalmost 7 years ago
Integra Offers Clear Advantage Product for NGS Library Preparationalmost 7 years ago
MilliporeSigma Launches ADC Express Servicesalmost 7 years ago
Novartis Collaborates with Microsoft for AI Innovation LabAdvertisement
Related to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement